Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
Kyowa Kirin will maintain the medium- to long-term financial targets it announced in February despite discontinuing all clinical trials of its atopic dermatitis drug candidate rocatinlimab, President and COO Abdul Mullick said at an investor briefing on March 4. Takeyoshi…
To read the full story
Related Article
- Kyowa Kirin Keeps Long-Term KPIs despite OX40 Setback, Ups 2026 Core Profit Outlook
May 11, 2026
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
- Kyowa Kirin Aims to Raise Core Margin to 30% on Late-Stage Launches
February 12, 2026
- Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
BUSINESS
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
- Datroway Snares US Approval in 1st-Line TNBC: Daiichi Sankyo
May 25, 2026
- Net Profit at 24 Japan Drug Makers Tops 2 Trillion Yen, Led by Astellas and Sumitomo
May 25, 2026
- Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
May 25, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…